2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.Peer-Reviewed Original ResearchConceptsEvent-free survivalAllo-HSCTOverall survivalChronic GVHDAllogeneic hematopoietic stem cell transplantAllogeneic stem cell transplantationMedian event-free survivalHematopoietic stem cell transplantAcute myeloid leukemia patientsMedian overall survivalPost allo-HSCTReduced intensity conditioningStem cell transplantStem cell transplantationLong-term outcomesMyeloid leukemia patientsMulti-center studyAcute graftComplete remissionHost diseaseSalvage therapyComplex cytogeneticsMyeloablative conditioningMedian ageCell transplant
2022
Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Shallis R, Saliba A, Stahl M, Bewersdorf J, Grenet J, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Kubiak M, Kota V, Dinner S, Goldberg A, Litzow M. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 1435-1437. DOI: 10.1182/blood-2022-167731.Peer-Reviewed Original Research
2021
Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept
Bewersdorf J, Tallman M, Stahl M. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Current Opinion In Oncology 2021, 33: 658-669. PMID: 34341323, DOI: 10.1097/cco.0000000000000778.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute myeloid leukemia patientsMaintenance therapyAllo-HCTOverall survivalIntensive chemotherapyMyeloid leukemiaPersistence of leukemic cellsSafety of maintenance therapyAllogeneic hematopoietic cell transplantationRelapse-free survivalDuration of remissionHematopoietic cell transplantationIndividualized therapeutic approachFLT3 inhibitor sorafenibCC-486Induction chemotherapyOS benefitDisease relapseCell transplantationInhibitor sorafenibImproved survivalPatient selectionTargeted agentsLeukemic cells
2019
The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia
Shallis RM, Boddu PC, Bewersdorf JP, Zeidan AM. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews 2019, 40: 100639. PMID: 31761380, DOI: 10.1016/j.blre.2019.100639.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInduction therapyAcute myeloid leukemia patientsMost acute myeloid leukemia (AML) patientsAML patients ageIntensive induction therapyLeukemic stem cell persistenceOptimal treatment modalityMyeloid leukemia patientsPatient-specific factorsAcute myeloid leukemiaAvailability of therapiesMedical comorbiditiesOlder patientsPatient ageIntensive therapyOrgan reserveTreatment algorithmEarly mortalityLongstanding recommendationsTreatment modalitiesSuch therapyLeukemia patientsMyeloid leukemiaPatientsTherapy